FAF
NVCR icon

Fjarde Ap-fonden’s NovoCure NVCR Stock Holding History

Fjarde Ap-fonden’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,286
Closed -$213K – 549
2023
Q4 		$213K Buy
14,286
+5,800
+68% +$77.6K ﹤0.01% 534
2023
Q3 		$137K Sell
8,486
-14,914
-64% -$430K ﹤0.01% 538
2023
Q2 		$971K Hold
23,400
– – 0.01% 517
2023
Q1 		$1.41M Hold
23,400
– – 0.02% 486
2022
Q4 		$1.72M Buy
23,400
+300
+1% +$22.6K 0.02% 477
2022
Q3 		$1.6M Hold
23,100
– – 0.02% 518
2022
Q2 		$1.6M Sell
23,100
-9,300
-29% -$701K 0.02% 518
2022
Q1 		$2.68M Sell
32,400
-4,800
-13% -$354K 0.03% 508
2021
Q4 		$2.79M Buy
+37,200
New +$3.73M 0.02% 511

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fjarde Ap-fonden's NVCR Position: Q1 2024 in Review

Fjarde Ap-fonden sold out of NovoCure (NVCR) in Q1 2024, closing a stake of 14,286 shares — an estimated $213K sold.

Fjarde Ap-fonden first reported a position in NVCR in Q4 2021 and held it in 9 quarters. The position peaked at $2.79M in Q4 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • Fjarde Ap-fonden reported no remaining NovoCure position as of Q1 2024 after selling out during the quarter.
  • Fjarde Ap-fonden sold 14,286 NovoCure shares in Q1 2024, an estimated $213K.
  • Fjarde Ap-fonden first reported a position in NovoCure in Q4 2021 and held it in 9 quarters.
  • Fjarde Ap-fonden's NovoCure position peaked at $2.79M in Q4 2021.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Fjarde Ap-fonden's 13F filing for Q1 2024, filed 25 Apr 2024.